# Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy

> **NCT04816916** · PHASE2 · TERMINATED · sponsor: **Axcella Health, Inc** · enrollment: 12 (actual)

## Conditions studied

- Hepatic Encephalopathy

## Interventions

- **DRUG:** AXA1665
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04816916
- **Lead sponsor:** Axcella Health, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-29
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Sponsor is stopping the study to focus company resources on other development programs.
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04816916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04816916, "Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04816916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*